Keyphrases
Additional Therapy
14%
Chemoresistant
14%
Chemotherapy
100%
Contemporary Management
100%
Disseminated Infection
14%
Dose-dense Chemotherapy
14%
Evidence Acquisition
14%
First-line Chemotherapy
14%
Germ Cell Tumor
71%
High-dose Chemotherapy
14%
Late Relapse
14%
Long-term Disease-free Survival
14%
Mass Independent
14%
Mature Teratoma
14%
MEDLINE
14%
Metastatic Germ Cell Tumor
14%
Non-seminomatous Germ Cell Tumor (NSGCT)
28%
Positron Emission Tomography
14%
Positron Emission Tomography-computed Tomography (PET-CT)
14%
Post-chemotherapy
100%
Post-chemotherapy Retroperitoneal Lymph Node Dissection
42%
Remission
14%
Resection
14%
Residual Disease
28%
Residual Mass
28%
Retroperitoneal Lymph Node Dissection (RPLND)
14%
Salvage Therapy
14%
Seminoma
28%
Serologic
14%
Survival Benefit
14%
Testis Cancer
100%
Tumor Marker
14%
Viable Tumor
14%
Medicine and Dentistry
Disease
16%
Disease Free Survival
16%
Disseminated Disease
16%
First-Line Chemotherapy
16%
Germinoma
100%
High Dose Chemotherapy
16%
Mature Teratoma
16%
Minimal Residual Disease
33%
Neoplasm
16%
Non Seminomatous Germinoma
33%
Positron Emission Tomography
16%
Positron Emission Tomography-Computed Tomography
16%
Retroperitoneal Disease
16%
Retroperitoneal Lymph Node Dissection
66%
Salvage Therapy
16%
Seminoma
33%
Surgery
16%
Testis Cancer
100%
Tumor Marker
16%